A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure

Cohort 1 Inclusion: * Healthy, age 18-40 Cohort 1 Exclusion: * Significant or chronic medical illness * Pregnant females * Smoking within one month of enrollment * Use of any prescription drugs within 4 weeks prior to dosing Cohort 2 Inclusion: * 30-70 year old subjects with a diagnosis of NYHA Class II-III heart failure * Ejection fraction less than or equal to 35% * Rest SPECT imaging within 90 days prior to enrollment Cohort 2 Exclusion: * Significant or chronic medical illness * Pregnant females * Known history of arrhythmogenic disorder or rhythm disorder